FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151923056> ?p ?o ?g. }

• W2151923056 endingPage "77" @default.
• W2151923056 startingPage "71" @default.
• W2151923056 abstract "Human corticotropin-releasing factor (hCRF) is an endogenous peptide responsible for the secretion and synthesis of corticosteroids. In animal models of peritumoral brain edema, hCRF has significant anti-edematous action. This effect, which appears to be independent of the release of adrenal steroids, appears mediated by a direct effect on endothelial cells. We conducted a feasibility and phase I study with hCRF given by continuous infusion to patients with brain metastasis.Peritumoral brain edema documented by MRI and the use of either no steroids or stable steroid doses for more than a week were required. MRIs were repeated at completion of infusion and estimations by dual echo-image sequence (Proton density and T2-weighted images) of the amount of peritumoral edema were performed. The study was performed in two stages. In the feasibility part, patients were randomized to receive either 0.66 or 1 microgram/kg/h of hCRF or placebo over 24 hours. The second part was a dose finding study of hCRF over 72 hours at escalating doses.Seventeen patients were enrolled; only one was receiving steroids (stable doses) at study entrance; dose-limiting toxicity (hypotension) was observed at 4 micrograms/kg/h x 72 hours in two out of four patients, while zero of five patients treated at 2 micrograms/kg/h developed dose-limiting toxicities. Flushing and hot flashes were also observed. Improvement of neurological symptoms and/or exam were seen in 10 patients. Only small changes were detected by MRI. Improvement in symptoms did not correlate with changes in cortisol levels, and changes in cortisol levels were not correlated with changes in peritumoral edema.hCRF is well tolerated in doses up to 2 micrograms/kg/h by continuous infusion x 72 hours. Hypotension limits administration of higher doses. The observation of clinical benefit in the absence of corticosteroids suggests hCRF may be an alternative to steroids for the treatment of patients with peritumoral brain edema. Further exploration of this agent in efficacy studies is warranted." @default.
• W2151923056 created "2016-06-24" @default.
• W2151923056 creator A5001759866 @default.
• W2151923056 creator A5002037553 @default.
• W2151923056 creator A5006312326 @default.
• W2151923056 creator A5015492315 @default.
• W2151923056 creator A5015548619 @default.
• W2151923056 creator A5021951341 @default.
• W2151923056 creator A5046771553 @default.
• W2151923056 creator A5063179337 @default.
• W2151923056 creator A5071938679 @default.
• W2151923056 creator A5072308451 @default.
• W2151923056 creator A5080900202 @default.
• W2151923056 creator A5082637703 @default.
• W2151923056 creator A5083381459 @default.
• W2151923056 creator A5087237814 @default.
• W2151923056 creator A5089143998 @default.
• W2151923056 date "1998-01-01" @default.
• W2151923056 modified "2023-09-26" @default.
• W2151923056 title "A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema" @default.
• W2151923056 cites W2013054764 @default.
• W2151923056 cites W2017944173 @default.
• W2151923056 cites W2032398883 @default.
• W2151923056 cites W2032468493 @default.
• W2151923056 cites W2035389637 @default.
• W2151923056 cites W2041322722 @default.
• W2151923056 cites W2063163870 @default.
• W2151923056 cites W2073388455 @default.
• W2151923056 cites W2130520030 @default.
• W2151923056 cites W2798061778 @default.
• W2151923056 doi "https://doi.org/10.1023/a:1008251426425" @default.
• W2151923056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9541686" @default.
• W2151923056 hasPublicationYear "1998" @default.
• W2151923056 type Work @default.
• W2151923056 sameAs 2151923056 @default.
• W2151923056 citedByCount "37" @default.
• W2151923056 countsByYear W21519230562013 @default.
• W2151923056 countsByYear W21519230562014 @default.
• W2151923056 countsByYear W21519230562016 @default.
• W2151923056 countsByYear W21519230562017 @default.
• W2151923056 countsByYear W21519230562018 @default.
• W2151923056 countsByYear W21519230562020 @default.
• W2151923056 countsByYear W21519230562021 @default.
• W2151923056 countsByYear W21519230562022 @default.
• W2151923056 crossrefType "journal-article" @default.
• W2151923056 hasAuthorship W2151923056A5001759866 @default.
• W2151923056 hasAuthorship W2151923056A5002037553 @default.
• W2151923056 hasAuthorship W2151923056A5006312326 @default.
• W2151923056 hasAuthorship W2151923056A5015492315 @default.
• W2151923056 hasAuthorship W2151923056A5015548619 @default.
• W2151923056 hasAuthorship W2151923056A5021951341 @default.
• W2151923056 hasAuthorship W2151923056A5046771553 @default.
• W2151923056 hasAuthorship W2151923056A5063179337 @default.
• W2151923056 hasAuthorship W2151923056A5071938679 @default.
• W2151923056 hasAuthorship W2151923056A5072308451 @default.
• W2151923056 hasAuthorship W2151923056A5080900202 @default.
• W2151923056 hasAuthorship W2151923056A5082637703 @default.
• W2151923056 hasAuthorship W2151923056A5083381459 @default.
• W2151923056 hasAuthorship W2151923056A5087237814 @default.
• W2151923056 hasAuthorship W2151923056A5089143998 @default.
• W2151923056 hasBestOaLocation W21519230561 @default.
• W2151923056 hasConcept C126322002 @default.
• W2151923056 hasConcept C142724271 @default.
• W2151923056 hasConcept C204787440 @default.
• W2151923056 hasConcept C27081682 @default.
• W2151923056 hasConcept C2776804153 @default.
• W2151923056 hasConcept C2780886150 @default.
• W2151923056 hasConcept C3019162651 @default.
• W2151923056 hasConcept C42219234 @default.
• W2151923056 hasConcept C71924100 @default.
• W2151923056 hasConcept C90924648 @default.
• W2151923056 hasConceptScore W2151923056C126322002 @default.
• W2151923056 hasConceptScore W2151923056C142724271 @default.
• W2151923056 hasConceptScore W2151923056C204787440 @default.
• W2151923056 hasConceptScore W2151923056C27081682 @default.
• W2151923056 hasConceptScore W2151923056C2776804153 @default.
• W2151923056 hasConceptScore W2151923056C2780886150 @default.
• W2151923056 hasConceptScore W2151923056C3019162651 @default.
• W2151923056 hasConceptScore W2151923056C42219234 @default.
• W2151923056 hasConceptScore W2151923056C71924100 @default.
• W2151923056 hasConceptScore W2151923056C90924648 @default.
• W2151923056 hasIssue "1" @default.
• W2151923056 hasLocation W21519230561 @default.
• W2151923056 hasLocation W21519230562 @default.
• W2151923056 hasOpenAccess W2151923056 @default.
• W2151923056 hasPrimaryLocation W21519230561 @default.
• W2151923056 hasRelatedWork W1972393871 @default.
• W2151923056 hasRelatedWork W1978167968 @default.
• W2151923056 hasRelatedWork W1983403674 @default.
• W2151923056 hasRelatedWork W1984226278 @default.
• W2151923056 hasRelatedWork W2051483231 @default.
• W2151923056 hasRelatedWork W2373829464 @default.
• W2151923056 hasRelatedWork W2435726602 @default.
• W2151923056 hasRelatedWork W2981730245 @default.
• W2151923056 hasRelatedWork W4205219468 @default.
• W2151923056 hasRelatedWork W4233016836 @default.
• W2151923056 hasVolume "9" @default.
• W2151923056 isParatext "false" @default.

• next